Aug 14, 2006 | NEWS
deCODE genetics (Nasdaq:DCGN) today announced that it has begun enrolling patients in its Phase I clinical development program for DG051, the company’s follow-on developmental compound for the prevention of heart attack. The ascending-dose, double-blind, randomized,...
Jun 29, 2006 | NEWS
June 29, 2006 deCODE genetics (Nasdaq: DCGN) today announced that it has submitted an investigational new drug application (IND) to the US Food and Drug Administration (FDA) for DG051, the company’s follow-on investigational compound for the prevention of heart...
Jun 24, 2006 | NEWS
June 24, 2006 deCODE genetics (Nasdaq:DCGN) today announced positive results from its preliminary Phase II clinical trial (Phase IIa) of Cephalon Inc.’s (Nasdaq: CEPH) CEP-1347 in asthma. Data on patients receiving active drug in the trial were consistent with a...
Jun 20, 2006 | NEWS
June 20, 2006 A population-based study by a team of deCODE scientists and colleagues at Iceland’s National University Hospital published today provides a detailed look at the impact of a gene variant on risk of breast cancer. The variant is within a gene called BARD1...
May 17, 2006 | NEWS
May 17, 2006 deCODE genetics (Nasdaq:DCGN) today announced the initiation of patient enrollment in the pivotal Phase III trial for DG031, deCODE’s lead developmental compound for the prevention of heart attack. “This is an important study for deCODE and a small...
